Merck & Co. stock heads into the open after a flat Nasdaq close

At the close on September 9, 2026, Merck & Co. stock finished the Nasdaq session virtually unchanged around USD 148 per share, with trading volume near its recent average and the Dow and S&P 500 both lower. Today the focus is on Merck at the Wells Fargo healthcare conference.

Merck & Co. stock closed on the Nasdaq at USD 148.52 on September 9, 2026, virtually unchanged from the prior session and implying a 0.0% daily move. Compared with the broader market, the shares held steady while the Dow Jones Industrial Average and the S&P 500 both lost ground on the same day.

September 9, 2026 in numbers

Merck & Co., Inc. (ISIN US58933Y1055, NYSE: MRK) ended the September 9, 2026 Nasdaq session at USD 148.52 after trading in an intraday range between roughly USD 147 and USD 149, with volume close to its recent average per Nasdaq data. A brief market update from Finanzen described the stock as nearly unchanged in New York trading that afternoon, consistent with the flat close. On the same day, the Dow Jones Industrial Average fell about 0.8% and the S&P 500 slipped roughly 0.5%, meaning Merck outperformed these benchmarks in the last completed session.

The share price is trading close to its 52-week high, according to a recent overview by Zacks, which noted that Merck shares have posted a strong year-to-date gain relative to the pharmaceutical industry. Separately, Benzinga reported on September 9, 2026 that Leerink Partners reiterated an outperform rating on Merck and raised its price target to USD 161, underscoring continued analyst confidence in the stock and potentially supporting its resilience against the broader market decline.

Conference appearances in focus today

Today, September 10, 2026, attention turns to Merck's participation in the Wells Fargo 21st Annual Healthcare Conference, where management presented on September 9, 2026 and continues to engage investors around its growth plans. As Investing.com reported, Merck outlined an expanded growth strategy at the Wells Fargo event, which keeps the company in focus for healthcare investors heading into today's US session. A detailed transcript of Merck's presentation, published by Seeking Alpha, shows executives discussing pipeline progress and capital allocation, themes that could influence sentiment on Merck & Co. stock as trading resumes today.